Still not losing weight on Wegovy 2.4mg? Understanding why progress stalls

Is this a real plateau or a normal slowdown?

The first thing worth separating is whether what you're experiencing is a true plateau or the predictable deceleration that almost everyone on semaglutide goes through. In the STEP 1 trial (68 weeks, 2.4mg semaglutide versus placebo) the rate of weight loss was steepest in the early months and slowed considerably by the halfway point, even among people who eventually reached strong overall results. That deceleration is not treatment failure; it reflects the body reaching a new, lower defended weight point while it recalibrates. A genuine plateau is something more specific: no meaningful change across six to eight weeks at maintenance dose, despite consistent adherence and no obvious changes in diet or activity. If you're a few weeks into 2.4mg and the weekly number has just flattened, that may simply be the normal shape of treatment. If it has been two months or more with no movement at all, that is worth discussing with your prescriber.

The NHS patient guide for semaglutide covers what to expect during treatment and when to seek advice, it is a useful first reference before drawing conclusions.

The factors that can blunt response at this dose

Several things independently reduce how much work semaglutide can do, and they tend to compound each other. Caloric intake is the obvious one, but the detail matters: protein adequacy is often the issue rather than overall calories. When appetite suppression cuts total food volume, people sometimes end up protein-deficient without realising it, and the body then loses proportionally more muscle than fat. That lowers the metabolic rate and makes further fat loss harder. It is worth logging honestly for a week, not to count every calorie forever, but to see where the composition actually sits.

Injection technique is underappreciated. Injecting into scar tissue from repeatedly using the same site reduces absorption meaningfully. Rotating between the abdomen, thigh and upper arm (and moving the exact spot within each area each week) keeps absorption consistent. Sleep and stress also matter biologically: elevated cortisol from poor sleep actively works against the appetite signals GLP-1 medicines rely on. Some prescribed medicines, including certain antidepressants, corticosteroids and antipsychotics, are known to affect weight regulation and can partially counteract semaglutide's effect; your prescriber can review this.

If you have been on lower doses and found progress slow there too, the pattern across the titration is informative. It can help to think back on whether weight loss stalled at 1mg Wegovy, or whether the 0.5mg starting dose produced little movement, before drawing conclusions about where the issue lies. You can also revisit how your body responded at 1.7mg before 2.4mg was reached.

What the 5% benchmark means, and what NICE says about it

NICE's appraisal of semaglutide for weight management (TA875) includes a specific checkpoint: if someone has not lost at least 5% of their starting body weight after six months at the maintenance dose, clinical guidance says continuing treatment should be reviewed. This does not mean treatment automatically stops, it means the prescriber looks at the whole picture and decides whether to continue, adjust, or consider alternatives. It is a clinical conversation, not an automatic cut-off.

Five per cent might sound modest, but for someone weighing 100kg at the start, that is five kilograms. If you are close to that threshold and losing slowly, you may still reach it with a little more time. If you are well below it after six months, that conversation needs to happen. Your prescriber is the right person to have it with, not a forum, not a self-managed protocol change.

For people wondering about what an alternative trajectory might look like, the full Wegovy dose schedule and the evidence behind it is worth reading alongside this context.

What actually comes next, and what it is not

There is no licensed dose of Wegovy above 2.4mg for the standard injection, so the question of what to do when 2.4mg is not producing results is a genuine clinical one. The answer depends on the individual. For some people, a careful re-examination of diet composition and activity is enough to restart progress. For others, the prescriber may consider whether the medicine is the right fit at all, or whether a different treatment is more suitable.

Tirzepatide (Mounjaro) works on two gut-hormone pathways rather than one, and head-to-head trial evidence favours it over semaglutide 2.4mg for average weight reduction, something a prescriber can discuss with you in context. That is not a reason to switch impulsively, but it is a legitimate clinical option worth raising. You can read more about the differences on the Wegovy overview or explore other licensed weight-loss treatments to understand the landscape before a consultation.

What is not appropriate is self-managing a switch, stopping abruptly, or buying treatment from a seller offering these medicines without a valid prescription. Wegovy is a prescription-only medicine; any change to treatment should go through a clinician who can assess your full picture. There are also real risks from counterfeit pens sold online, the MHRA has warned publicly about fake weight-loss injections, including large seizures of counterfeit product in 2025, and urges anyone buying online to verify a pharmacy on the GPhC register before purchasing.

If you are weighing up whether to continue with Wegovy or explore other options, a prescriber can review your progress and your history in a single consultation. You can check your eligibility and speak to the clinical team at nume to work out what makes sense for your situation. Information on how nume prices treatment transparently is on the Wegovy prices page.